Propositions belonging to the thesis:

IMMUNE TREATMENTS OF SOLID TUMORS AND T CELL MONITORING

- 1. Monitoring of CAR T cells in patients by flow cytometry provides exact CAR T cell numbers, which are difficult to retrieve from DNA levels. (Chapter 2)
- 2. Measurements of plasma levels of IFN-γ and IL-6 during T-cell therapy should be a routine measurement as indicators for CAR T-cell persistence and in vivo-activity. (Chapter 2)
- 3. T cell persistence in patients following adoptive T cell therapy is enhanced by increased fractions of T naïve cells before transduction. (Chapter 3)
- 4. Monitoring T cells specific for single antigens in peripheral blood upon therapy with tumor lysate-loaded DCs is not useful. **(Chapter 6)**
- 5. Differences in T cell quantity, phenotype and tumor characteristics suggest that soft tissue sarcoma subtypes require different immunotherapeutic approaches. (Chapter 7)
- 6. A serious flaw in cancer treatment is underestimation of the extent of tumor heterogeneity. (adapted from Longo, NEJM 2012)
- 7. Tumor samples collected at the time of therapeutic intervention are essential to elucidate the molecular and cellular interactions between tumor cells and the immune microenvironment, which in turn is necessary to identify optimal (combination) therapies. (adapted from Hedge, CCR 2016)
- 8. For CAR T cell therapy to be successful towards solid tumors, combination with other therapeutic modalities is essential to overcome local immune suppressive mechanisms. (adapted from Morgan, Front. Immunol. 2018)
- Scientific performance should not be measured by the number of publications since this
 results in 'easy publishable' results and goes at the expense of quality of science.
 (adapted from Tijdink, PLOS One, 2013)
- In order to guarantee the quality of healthcare, tough choices about the allocation of funds are inevitable since funds are not infinite. (adapted from Bos, Volkskrant 12-10-2018)
- 11. If you keep doing things the way you have always done them, you will always keep getting the same outcome you have always had before.